Antineoplastic Agents, Immunological Concept

subject area of

• A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies  Conference Paper
• Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature  Academic Article
• Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?  Academic Article
• Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial  Academic Article
• Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma  Academic Article
• Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium  Academic Article
• Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events  Academic Article
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial  Academic Article
• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study  Academic Article
• Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma  Academic Article
• Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*  Academic Article
• Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites  Academic Article
• Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors  Academic Article
• Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review  Academic Article
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer  Academic Article
• Immunotherapy in the Elderly  Academic Article
• Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses  Academic Article
• Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab  Academic Article
• Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial  Academic Article
• Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013  Academic Article
• Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases  Academic Article
• Real-World Benefit of Nivolumab in A Canadian Non-Small-Cell Lung Cancer Cohort  Academic Article
• Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis  Academic Article
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review  Academic Article
• Targeted therapy for metastatic renal cell carcinoma  Academic Article
• The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma  Academic Article
• The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?  Academic Article